



An update on *Helicobacter pylori* infection in renal failure patients

Mohammad Reza Ardalan¹, Saeed Mardani², Shahin Asgari-Savadjani², Mohamad Reza Tamadon³, Shirin Naghdifar⁴, Hamid Nasri^{4*}

¹Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

²Department of Internal Medicine, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

³Department of Internal Medicine, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

⁴Nickan Research Institute, Isfahan, Iran

Correspondence to

Prof. Hamid Nasri;

Email: hamidnasri@med.mui.ac.ir

Received 2 February 2016

Accepted 27 March 2016

Published online 10 April 2016

Keywords: *Helicobacter pylori*, Chronic kidney disease, Hemodialysis, End-stage renal disease

Abstract

Helicobacter pylori (*H. pylori*) is a gram negative spiral rod bacterium which inhabits gastric mucosa and attaches to the gastric epithelium using specific receptor. *H. pylori* infection endures as one of the most challenging diseases triggering high mortality and morbidity. *H. pylori* infection is reported as the cause of gastric cancer, chronic gastritis, peptic ulcer and other gastrointestinal disorders. It was suggested that long-term *H. pylori* infection may aggravate chronic kidney disease (CKD) complications and cardiovascular disease (CVD) risk factors. Patients with chronic renal failure often possess gastrointestinal symptoms including decline of gastrointestinal motility, amyloid protein deposition and decreased sensory disturbance. Hence, in patients with chronic renal failure, the nutrition status is poor which usually leads to the development of malnutrition. This status will increase the morbidity and mortality of these patients. These patients in comparison to individuals with normal renal function usually have higher risks of gastric mucosal damage due to hypergastrinemia, enhanced inflammation, local chronic circulatory failure and high level of ammonia. Majority of these patients (25%–75%) usually suffer from gastrointestinal complications such as gastric erosions, gastrointestinal bleeding, peptic ulcers and angiodysplasia. The aim of the present study was to review the relation between one of the most challenging diseases, called *H. pylori* infection, and end-stage renal disease (ESRD), diabetic and chronic hemodialysis individuals as well as presenting the treatment strategies of this infection.

Citation: Ardalan MR, Mardani S, Asgari-Savadjani S, Tamadon MR, Naghdifar S, Nasri H. An update on *Helicobacter pylori* infection in renal failure patients. *Immunopathol Persa*. 2016;2(2):e10.

Introduction

Helicobacter pylori (*H. pylori*) is a gram negative spiral rod bacterium which inhabits gastric mucosa (1-4) and attaches to the gastric epithelium using specific receptor (5,6). *H. pylori* infection endures as one of the most challenging diseases triggering high mortality and morbidity (7,8). *H. pylori* infection is reported as the cause of gastric cancer, chronic gastritis, peptic ulcer and other gastrointestinal disorders (9-13). Then, bacterial infection is a basic problem in patients especially those who are hospitalized. Recently, several reports have been published reporting the relation of *H. pylori* infection and kidney failure especially chronic renal failure or diabetes diseases.

Chronic renal failure and gastrointestinal

Patients with chronic renal failure often possess gastrointestinal symptoms including

Key point

Helicobacter pylori (*H. pylori*) is a gram negative spiral rod bacterium which inhabits gastric mucosa and attaches to the gastric epithelium using specific receptor. *H. pylori* is one of the most challenging diseases which is important for public health. *H. pylori* infection endures as one of the most challenging diseases triggering high mortality and morbidity. *H. pylori* infection is reported as the cause of gastric cancer, chronic gastritis, peptic ulcer and other gastrointestinal disorders. It was suggested that long-term *H. pylori* infection may aggravate chronic kidney disease (CKD) complications and cardiovascular disease (CVD) risk factors.

decline of gastrointestinal motility, amyloid protein deposition and decreased sensory disturbance (14). Hence, in patients with



chronic renal failure, the nutrition status is poor which usually leads to the development of malnutrition. This status will increase the morbidity and mortality of these patients. These patients in comparison to individuals with normal renal function usually have higher risks of gastric mucosal damage due to hypergastrinemia, enhanced inflammation, local chronic circulatory failure and high level of ammonia. Majority of these patients (25%–75%) usually suffer from gastrointestinal complications such as gastric erosions, gastrointestinal bleeding, peptic ulcers and angiodysplasia (15). The aim of the present review paper was to review the relation between one of the most challenging diseases, called *H. pylori* infection, and end-stage renal disease (ESRD), diabetic and chronic hemodialysis individuals as well as presenting the treatment strategies of this infection.

Materials and Methods

This review article discusses recent findings on *Helicobacter pylori* infection in renal diseases. For this review, we used a variety of sources by searching through Web of Science, PubMed, EMBASE, Scopus and directory of open access journals (DOAJ). The search was performed using combinations of the following key words and or their equivalents such as chronic renal failure, end-stage renal disease, *Helicobacter pylori*, diabetic nephropathy, chronic kidney disease and hemodialysis

H. pylori infection in ESRD patients

The relationship between *H. pylori* infection and ESRD events remains unknown. The risk of ESRD noticeably is increased in patients with *H. pylori* infection combined with at least one of the following concomitant comorbidities: diabetes, hypertension, hyperlipidemia and coronary artery disease (1). *H. pylori* infection is one of the main factors for dyspepsia and recently has been investigated for in end-stage its possible role in renal disease. Dyspepsia is a pain in the upper part of the abdomen which is a usual complication in chronic kidney disease (CKD) patients and dialysis patients (16). *H. pylori* infection was related to a subsequent risks of ESRD thus, it has been determined that *H. pylori*-infected patients with cardiovascular disease (CVD) or concomitant chronic kidney disease risk factors were at a higher risk of ESRD than those who had a single CVD or CKD risk factor. Hence, it was suggested that long-term *H. pylori* infection augments various complications of CKD and CVD risk factors, causing a decrease in renal function followed by ESRD, as noticed in the *H. pylori*-infected group (1). *H. pylori* also plays an important role on the aggravation of complications of chronic hemodialysis patients and its complications too (17).

H. pylori infection in diabetic nephropathy, hemodialysis and chronic renal failure patients

H. pylori infection is common in diabetics specially is higher in patients with type-2 diabetes mellitus compared to normal population. In this regard, a study was done but no significant relation was found amongst the serum *H.*

pylori IgG antibody titer and magnesium levels and the age of patients, duration of diabetes and creatinine clearance. There was just a positive correspondence between *H. pylori* infection and serum magnesium. They confirmed that this correspondence might facilitate the colonization of *H. pylori* in the stomach of patients on hemodialysis but not in patients with various stages of renal failure who were not undergoing hemodialysis (18).

In studies, the value of serum *H. pylori* specific IgG antibody value could be applicable because it is as a sign of *H. pylori* infection although some authors did not find any significant difference of various biochemical parameters between females and males, diabetics and non-diabetics and serum *H. pylori* IgG antibody titer. But they found significant negative relation between serum magnesium and serum intact PTH levels and serum *H. pylori* IgG antibody titer. Otherwise, some investigators found a positive correlation between *H. pylori* infection and serum magnesium. In this regard, to understand the worsening factors of *H. pylori* infection in chronic kidney disease, particularly in hemodialysis patients, Hafizi et al conducted a study on 44 hemodialysis patients or other research on 94 type-2 diabetic patients. They found a significant positive relation of serum magnesium with *H. pylori* antibody. Thus, it seems the presence of an association of *H. pylori* infection with serum magnesium. It is clear that magnesium ion attainment is essential for *H. pylori* (19). In this regard, the high serum magnesium level in the gastric mucosa could facilitate the colonization of *H. pylori* in the stomach of patients on hemodialysis, but not in patients with different stages of renal failure that were not on hemodialysis (8, 19). Conversely, magnesium is mostly excreted by kidney and magnesium metabolism is interrupted in patients with chronic renal failure. Actually, elevated serum magnesium level can be an obstacle in patients on maintenance hemodialysis. Although, the kidneys are the major way of excretion of magnesium from the body, increased serum magnesium would be expected in hemodialysis patients and in patients with renal failure (19).

In the report of Hosseini et al, it was shown that the occurrence of *H. Pylori* infection in renal transplant patients and the normal population is the same (20). Lately, many evidences have shown that *H. pylori* is associated with extra-gastrointestinal diseases including idiopathic thrombocytopenic purpura, iron deficiency anemia and diabetes mellitus. Also, patients with chronic renal failure usually suffer from local or systemic chronic circulatory failure or both of them, high ammonia, hypergastrinemia and improved inflammation that facilitates *H. pylori* infection. Gu et al, investigated the association between infection of *H. pylori* and the different types of dialysis and then they found that *H. pylori* infection was not statistically related to hemodialysis specifically. So, their results showed that prevalence of *H. pylori* infection was similar between chronic renal failure (CRF) patients who were receiving dialysis and the control cluster with normal renal function. Some investigators, however, realized that the prevalence of *H. pylori* in CRF patients suffering dialysis was consid-

erably lower than in non-CRF controls without or with gastrointestinal symptoms (21-26). The fact is that the majority of CRF patients who receive dialysis inevitably have access to antibiotics, H₂ receptor antagonists or proton pump inhibitors which then affect the *H. pylori* infection rate to some extent. Also, gastric atrophy progresses along with reduced secretion of acid in addition to higher levels of pro-inflammatory cytokines in CRF patients causing *H. pylori* infection difficult to survive (27,28).

Relation between *H. pylori* infection and urea concentration

H. pylori is known to change acid secretory physiology in patients with chronic infection. Subsequent acid hypersecretion and hypergastrinemia are key factors in the gastroduodenal lesions and pathophysiology of peptic ulcer disease in these patients and more evident in patients with ESRD. Therefore, detection and then treatment of gastroduodenal lesions are pretty important especially in preventing the complications after renal transplantation. Various investigations were conducted to investigate whether urea concentration or uremia in gastric secretion causes an appropriate environment for infection of *H. pylori* (29-33). However, on the other hand, other investigation have detected the frequency of *H. pylori* infection in uremia is 34%-47% and in kidney transplanted patients is 38%. Some studies have reported the frequency of *H. pylori* infection in patients with ESRD on hemodialysis is 34%-75% (34). The majority of patients with ESRD on hemodialysis experienced gastrointestinal discomfort. It is assumed that uremia can alter the bacterial colonization of the upper gastrointestinal tract and hence, reducing infection of *H. pylori* (35).

Relation between *H. pylori* infection and vitamin D level

25-hydroxy vitamin D (25-OH Vit D) is the main circulating metabolite of vitamin D even though the biologically active form of vitamin D is 1,25(OH)₂ vitamin D, made in the kidney, it is generally accepted that the amount of circulating 25-OH vitamin D provides better information with respect to the patients vitamin D status and is used for the finding of hypovitaminosis. Generally, the presence of the vitamin D receptor shows that cells are responsive to vitamin D. Apart from enterocytes, osteoblasts and distal renal tubular cells, the vitamin D receptors is found in lots of other cell types, including parathyroid gland cells, colon cells, skin keratinocytes, ovarian cells and pituitary gland cells. The vitamin D receptor is also generally expressed in most cell types of the immune system, i.e., B cells, T cells, macrophages, monocytes, dendritic cells and NK cells. It has been detected that high blood urea nitrogen values could associated with a low occurrence of *H. Pylori* infection, and that patients on hemodialysis could be protected against this infection due to state of immune deficiency. We previously shown the influence of serum 25-hydroxy vitamin D levels on *H. pylori* infections in 36 patients with end-stage kidney failure on regular hemo-

dialysis. The serum *H. pylori* specific IgG antibody values and serum 25-OH vitamin D level were assessed through an enzyme-linked immunosorbent assay (ELISA) method. The study patients were including 15 females and 21 males. The mean age of the study group was 47 (±17) years. The average level of serum 25-OH vitamin D was 0.5 ± 18.7 nmol/l (median: 3.5 nmol/l) whereas the average value of serum *H. pylori* specific IgG antibody titer was 7.7 (±9.9) U/mL (median: 2 U/mL). Thus an important positive association was obtained amongst the levels of serum 25-OH vitamin D and serum *H. pylori* specific IgG antibody titers (data adjusted for age, urea reduction rate, duration and dose of dialysis) ($r = 0.36, P = 0.043$). In this study, we suggested that vitamin D could positively affect the chronic inflammatory status of dialysis patients and could potentiate the immune response in such patients. According of this immuno-modulatory effect, vitamin D analogs could offer new means to control the inflammatory status in patients on upkeep dialysis (36). Moreover, in our another studies an inverse association of serum albumin with *H. pylori* IgG antibody level and dialysis efficacy as well as positive association of *H. pylori* IgG antibody level with the duration of hemodialysis treatment, were also detected which imply an inverse correlation of *H. pylori* infection with malnutrition and the resultant immuno-deficiency of hemodialysis patients (37-39).

H. pylori infection and kidney transplantation

Before the discovery of proton pump inhibitors and H₂ blockers, usually the *H. pylori* infected disease would lead to serious complications following kidney transplantation. Therefore, in some centers, ulcer surgery was advocated before kidney transplant. Following the introduction and usage of ranitidine as ulcer prophylaxis following kidney transplantation, the number of serious kidney and upper gastrointestinal complications decreased substantially (40). Nowadays, *H. pylori* is accepted as a major etiologic factor in gastritis and gastroduodenal ulceration. During an acute rejection episode effective ulcer prophylaxis seemed to be important in patients regardless of their *H. pylori* status, especially in patients who were also receiving prophylactic aspirin treatment. Some centers have suggested that although *H. pylori* infections are common in kidney transplant patients, however these patients do not increase the risk of postoperative gastroduodenal complications (41).

H. pylori infection and anemia

Anemia is a constant finding in renal disease, affecting about more than 90% of patients, and the major role of anemia in the expansion of cardiovascular dysfunction is founded, anemia of ESRD could be accomplished relatively effectively by recombinant human erythropoietin. In this regard we previously conducted a cross-sectional study on maintenance hemodialysis patients. In this research was examined the aggravation of anemia by *H. pylori* on 39 patients with ESRD undergoing routine hemodialysis treatment. Average ages of patients were 46 (±18) years. All patients had dissimilar upper gastrointestinal

complaints including epigastric burning, epigastric pain, early satiety, postprandial fullness, bloating and belching. The duration of hemodialysis was 30 (\pm 35) months (median: 18 months). Mean \pm SD of hematocrit and hemoglobin level of all patients were $28 \pm 6\%$ (median: 29%) and 9 ± 2 g/dL (median: 9 g/dL) respectively. The rate of serum *H. pylori* particular IgG antibody titers of all patients was $7.6 (\pm 9.9)$ U/mL (median: 2 U/mL). In this examination no significant difference of *H. pylori* IgG antibody level amongst females and males or diabetic and non-diabetic hemodialysis patients were seen. In this study in male cluster an important inverse relation amongst logarithm of *H. pylori* IgG antibody level and serum hematocrit and hemoglobin were understood. Furthermore, in this cluster an imperative inverse relation amongst logarithm of *H. pylori* IgG antibody level and serum iron were seen. Furthermore, no important relationship among serum *H. pylori* IgG antibody level and serum iron, hematocrit and hemoglobin in all patients, female, diabetic and non-diabetics hemodialysis cluster were perceived. In this research no important relationship among serum *H. pylori* IgG antibody level and serum ferritin in all clusters was seen. Thus, it was shown that presence of *H. pylori* infection is related to a poorer response to oral iron therapy which develops with treatment for *H. pylori* infection. In patients on regular hemodialysis could be shown an inverse relation amongst *H. pylori* infection with hematocrit and hemoglobin level in addition to with serum iron, implies further attention to infection of *H. pylori* in these patients which one their major problem is anemia, so aggravation of *H. pylori* infection with anemia needs aggressive treatment of *H. pylori* infection in study patients (42).

Diagnosis and treatment of *H. pylori* infection

H. pylori infection can be diagnosed with both noninvasive and invasive tests. Invasive tests include culture, histology and rapid urease test that require endoscopy to obtain biopsies of the gastric mucosa and noninvasive tests include analysis of samples of blood, stool or breath including urease breath test (UBT) and *H. pylori* stool antigen (HPSA). Noninvasive tests are beneficial for primary diagnosis, when a treatment sign previously exists, or to monitor treatment success or failure. They are also beneficial in patients who cannot tolerate endoscopy, children, and epidemiological population studies. These tests have been introduced as reliable tests to screen *H. pylori* infection until recently in patients with kidney failure (43). Amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ) are still used for treating of *H. pylori* infection. However, the efficiency of legacy triple regimens has been really challenged, and they are progressively becoming ineffective. Moreover, some areas in Asia show patterns of emerging antimicrobial resistance. More effective regimens such as the bismuth and non-bismuth quadruple, sequential, and dual-concomitant (hybrid) regimens are now substituting standard triple therapies as empirical first-line treatments on the base of the understanding of the local prevalence of *H. pylori* antimicrobial

resistance (44). The North American Society and the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) proposed for first-line therapy including triple therapy with a proton pump inhibitor (PPI) and Imidazole or Clarithromycin and Amoxicillin; therapy with bismuth salt, Imidazole and Amoxicillin; or sequential therapy (45).

Conclusion

H. pylori is one of the most challenging diseases which is important for public health. *H. pylori* associates with ESRD, diabetic nephropathy and HD. Magnesium ion is essential for *H. pylori* to facilitate the colonization of this bacteria in the stomach of patients. However, urea concentration relates to *H. pylori* as well. Uremia can change bacterial colonization of the upper gastrointestinal tract and then reduces *H. pylori* infection. So, we should be aware of *H. pylori* infection and try to diagnose and treat this disease at least time.

Authors' contribution

Searching the data conducted by SAS, SN and MRT. SN, SM and MRA prepared the primary draft. HN edited the manuscript. All authors read and sign the final paper.

Conflicts of interest

The authors declared no competing interests.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support

None.

References

1. Lin SY, Lin CL, Liu JH, Yang YF, Huang CC, Kao CH. Association between *Helicobacter pylori* infection and the subsequent risk of end-stage renal disease: a nationwide population-based cohort study. *Int J Clin Pract*. 2015;69:604-10.
2. Bagheri N, Azadegan-Dehkordi F, Sanei H, Taghikhani A, Rahimian G, Salimzadeh L, et al. Associations of a TLR4 single-nucleotide polymorphism with *H. pylori* associated gastric diseases in Iranian patients. *Clin Res Hepatol Gastroenterol*. 2014;38:366-71.
3. Bagheri N, Rahimian G, Salimzadeh L, Azadegan F, Rafieian-Kopaei M, Taghikhani A, et al. Association of the virulence factors of *Helicobacter pylori* and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients. *EXCLI J*. 2013;12:5-14.
4. Bagheri N, Taghikhani A, Rahimian G, Salimzadeh L, Azadegan Dehkordi F, Zandi F, et al. Association between virulence factors of *Helicobacter pylori* and gastric mucosal interleukin-18 mRNA expression in dyspeptic patients. *Microb Pathog*. 2013;65:7-13.
5. Hooman N, Mehrazma M, Talachian E, Otukesh H, Nakhaii S. *Helicobacter pylori* infection in pediatric candidates for kidney transplantation. *Iran J Kidney Dis*. 2011;5:124-9.
6. Rahimian G, Sanei MH, Shirzad H, Azadegan-Dehkordi F, Taghikhani A, Salimzadeh L, et al. Virulence factors of *Helicobacter pylori* vacA increase markedly gastric mucosal TGF-beta1 mRNA expression in gastritis patients. *Microbial pathogenesis*. 2014;67-68:1-7.
7. Tamadon MR. Comment on: Significant association of serum *H. pylori* IgG antibody titer with kidney function in renal transplanted patients. *J Renal Inj Prev*. 2013;2:7-8.

8. Baradaran A, Nasri H. Association of Helicobacter pylori IgG antibody with various demographic and biochemical parameters in kidney transplant recipients. Saudi J Kidney Dis Transpl. 2011 Nov;22:1115-20.
9. Nasri H, Rafieian-Kopaei M. Significant association of serum H. pylori IgG antibody titer with kidney function in renal transplanted patients. J Renal Inj Prev. 2013;2:23-5.
10. Salimzadeh L, Bagheri N, Zamanzad B, Azadegan-Dehkordi F, Rahimian G, Hashemzadeh-Chaleshtori M, et al. Frequency of virulence factors in Helicobacter pylori-infected patients with gastritis. Microbial Pathogenesis. 2015;80:67-72.
11. Razavi A, Bagheri N, Azadegan-Dehkordi F, Shirzad M, Rahimian G, Rafieian-Kopaei M, et al. Comparative immune response in children and adults with H. pylori infection. J Immunol Res. 2015;2015:315957.
12. Bagheri N, Azadegan-Dehkordi F, Shirzad H, Rafieian-Kopaei M, Rahimian G, Razavi A. The biological functions of IL-17 in different clinical expressions of Helicobacter pylori-infection. Microbial pathogenesis. 2015;81:33-8.
13. Bagheri N, Azadegan-Dehkordi F, Shirzad M, Zamanzad B, Rahimian G, Taghikhani A, et al. Mucosal interleukin-21 mRNA expression level is high in patients with Helicobacter pylori and is associated with the severity of gastritis. Centr Eur Immunol. 2015;40:61-7.
14. Strid H, Simren M, Stotzer PO, Abrahamsson H, Björnsson ES. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol. 2004; 39:516-20.
15. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438-41.
16. Khedmat H, Taheri S. Current knowledge on helicobacter pylori infection in end stage renal disease patients. Saudi J Kidney Dis Transpl. 2009;20:969-74.
17. Nasri H. Helicobacter pylori infection and its relationship to plasma magnesium in hemodialysis patients. Bratisl Lek Listy. 2007;108:506-9.
18. Baradaran A, Nasri H. Helicobacter pylori specific IgG antibody and serum magnesium in type-2 diabetes mellitus chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2011;22:282-5.
19. Hafizi M, Mardani S, Borhani A, Ahmadi A, Nasri P, Nasri H. Association of helicobacter pylori infection with serum magnesium in kidney transplant patients. J Renal Inj Prev. 2014;3:101-5.
20. Hosseini SM, Sharifipour F, Nazemian F, Ghanei H, Zivarifar HR, Fakharian T. Helicobacter pylori eradication in renal recipient: triple or quadruple therapy? Acta Med Iran. 2014;52:271-4.
21. Araki H, Miyazaki R, Matsuda T, Gejyo F, Koni I. Significance of serum pepsinogens and their relationship to Helicobacter pylori infection and histological gastritis in dialysis patients. Nephrol Dial Transplant. 1999;14:2669-75.
22. Sugimoto M, Sakai K, Kita M, Imanishi J, Yamaoka Y. Prevalence of Helicobacter pylori infection in long-term hemodialysis patients. Kidney Int. 2009;75:96-103.
23. Shousha S, Arnaout AH, Abbas SH, Parkins RA. Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol. 1990;43:397-9.
24. Chang WC, Jo YI, Park HS, Jegal J, Park JH, Lee JH, et al. Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients. Clin Exp Nephrol. 2010;14:469-73.
25. Gu M, Xiao S, Pan X, Zhang G. Helicobacter pylori infection in dialysis patients: a meta-analysis. Gastroenterol Res Pract. 2013;2013:785892.
26. Azadegan-Dehkordi F, Bagheri N, Shirzad H, Rafieian-Kopaei M. The role of Th1 and Th17 cells in glomerulonephritis. J Nephropathol. 2015;4:32-7.
27. Paimela H, Stenman S, Kekki M, Sipponen P, Tallgren LG, Scheinin TM. Chronic gastritis and gastric acid secretion in uraemic and renal transplant patients. Hepatogastroenterology. 1985;32:15-9.
28. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology. 2002;123:1793-803.
29. Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, et al. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut. 1990;31:522-5.
30. el-Omar E, Penman I, Dorrian CA, Ardill JE, McColl KE. Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. Gut. 1993;34:1060-5.
31. Yildiz A, Besik F, Akkaya V, Sever MS, Bozfakioglu S, Yilmaz G, et al. Helicobacter pylori antibodies in hemodialysis patients and renal transplant recipients. Clin Transplant. 1999;13:13-6.
32. Kim H, Park C, Jang WI, Lee KH, Kwon SO, Robey-Cafferty SS, et al. The gastric juice urea and ammonia levels in patients with Campylobacter pylori. Am J Clin Pathol. 1990;94:187-91.
33. Abdulrahman IS, Al-Mueilo SH, Ismail MH, Yasawy MI, Al-Qahtani FN, Al-Qorain AA. Does Helicobacter pylori infection in chronic renal failure increase the risk of gastroduodenal lesions? A prospective study. Saudi J Gastroenterol. 2004;10:78-85.
34. Munoz de Bustillo E, Sanchez Tomero JA, Sanz JC, Moreno JA, Jimenez I, Lopez-Brea M, et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron. 1998;79:55-60.
35. Simenhoff ML, Saukkonen JJ, Burke JF, Wesson LG, Jr., Schaedler RW, Gordon SJ. Bacterial populations of the small intestine in uremia. Nephron. 1978;22:63-8.
36. Nasri H, Baradaran A. The influence of serum 25-hydroxy vitamin D levels on Helicobacter pylori infections in patients with end-stage renal failure on regular hemodialysis. Saudi J Kidney Dis Transpl. 2007;18(2):215-9.
37. Baradaran A, Nasri H. Helicobacter pylori IgG specific antibodies in association with serum albumin in maintenance hemodialysis patients. Pak J Nutr. 2005;4:265-9.
38. Nasri H, Baradaran A. Secondary hyperparathyroidism in association with malnutrition - inflammation complex syndrome in chronic hemodialysis. Ann King Edward Med Coll. 2005;11:301-6.
39. Nasri H. Serum C-reactive protein (CRP) in association with various nutritional parameters in maintenance hemodialysis patients. Bratisl Lek Listy. 2005;106:390-5.
40. Owens ML, Passaro E Jr, Wilson SE, Gordon HE. Treatment of peptic ulcer disease in renal transplant patient. Ann Surg. 1977;186:17-21.
41. Sarkio S, Rautelin H, Kyllönen L, Honkanen E, Salmela K, Halme L. Should Helicobacter pylori infection be treated before kidney transplantation? Nephrol Dial Transplant. 2001; 16:2053-57.
42. Nasri H. Aggravation of anemia by Helicobacter pylori infection in maintenance hemodialysis patients. Pak J Nutr. 2006;5:172-175.
43. Falaknazi K, Jalalzadeh M, Vafaeimanesh J. Noninvasive stool antigen assay for screening of Helicobacter pylori infection and assessing success of eradication therapy in patients on hemodialysis. Iran J Kidney Dis. 2010;4:317-21.
44. Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-92.
45. Koletzko S, Jones NL, Goodman KJ, Gold B, Rowland M, Cadranel S, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230-43.